Wide Ranks

CASI

CASI Pharmaceuticals, Inc.

3.97

Top Statistics
Market Cap 61 M Forward PE -1.86 Revenue Growth -59.50 %
Current Ratio 3.88 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -117.68 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -3.37 Enterprise / Revenue 3.37 Price To Sales Trailing12 Months 2.66
Profitability
Profit Margins -117.68 % Operating Margins -240.11 %
Balance Sheet
Total Cash 12 M Total Cash Per Share 0.9410 Total Debt 18 M
Total Debt To Equity 204.69 Current Ratio 3.88 Book Value Per Share 1.81
All Measures
Short Ratio 236.00 % Message Board Id finmb_354853 Shares Short Prior Month 146465
Return On Equity -0.8543 City Beijing Uuid 5244ad8d-dd52-32c9-8a35-41a17d71c051
Previous Close 4.14 First Trade Date Epoch Utc 834 M Book Value 1.81
Beta 0.6500 Total Debt 18 M Volume 27458
Price To Book 2.20 Last Split Date 1 B Fifty Two Week Low 2.05
Total Cash Per Share 0.9410 Total Revenue 23 M Shares Short Previous Month Date 1 B
Target Median Price 6.00 Max Age 86400 Sand P52 Week Change 0.3133
Operating Margins -240.11 % Target Mean Price 6.00 Net Income To Common -27205000
Short Percent Of Float 0.0069 Implied Shares Outstanding 15 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 42740 Average Volume10days 42740
Total Cash 12 M Next Fiscal Year End 1 B Revenue Per Share 1.72
Held Percent Insiders 0.4792 Ebitda Margins -99.91 % Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 4.14
Target Low Price 6.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 5.64
Open 4.10 Dividend Yield 0.00 % Return On Assets -0.2660
Time Zone Short Name EST Trailing Eps -2.23 Day Low 3.97
Address1 1701-1702, China Central Office Tower 1 Shares Outstanding 15 M Price Hint 4
Target High Price 6.00 Website https://www.casipharmaceuticals.com 52 Week Change -0.2898
Average Volume 30643 Forward Eps -2.13 Recommendation Key none
Compensation As Of Epoch Date 1 B Quick Ratio 213.60 % Last Split Factor 1:10
Regular Market Day High 4.18 Is_sp_500 False Profit Margins -117.68 %
Debt To Equity 204.69 Fifty Two Week High 8.48 Day High 4.18
Shares Short 75573 Regular Market Open 4.10 Industry Key biotechnology
Earnings Growth 0.00 % Enterprise To Revenue 3.37 Revenue Growth -59.50 %
Shares Percent Shares Out 0.0049 Currency USD Time Zone Full Name America/New_York
Market Cap 61 M Is_nasdaq_100 False Zip 100025
Quote Type EQUITY Industry Biotechnology Long Name CASI Pharmaceuticals, Inc.
Regular Market Day Low 3.97 Held Percent Institutions 0.2601 Current Price 3.97
Address2 No. 81 Jianguo Road Chaoyang District Enterprise To Ebitda -3.37 Financial Currency USD
Current Ratio 3.88 Gross Margins 56.81 % Industry Disp Biotechnology
Number Of Analyst Opinions 1 Country China Float Shares 5 M
Two Hundred Day Average 4.93 Enterprise Value 77 M Price To Sales Trailing12 Months 2.66
Forward PE -1.86 Regular Market Volume 27458 Ebitda -23079500
Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally.

It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma.

The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants.

The company has licensing agreements with Juventas Cell Therapy Ltd.

; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.

L.

C.

to develop and commercialize its commercial product EVOMELA.

It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co.

, Ltd; Pharmathen Global BV; and Riemser Pharma GmbH.

CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.